Volume 18, Number 4—April 2012
Serologic Evidence of Orthopoxvirus Infection in Buffaloes, Brazil
To the Editor: Since 1999, several exanthematous vaccinia virus (VACV) outbreaks affecting dairy cattle and rural workers have been reported in Brazil (1,2). VACV, the prototype of the genus Orthopoxvirus (OPV), exhibits serologic cross-reactivity with other OPV species and was used during the World Health Organization smallpox eradication campaign (3). The origin of VACV in Brazil is unknown, although some studies have suggested that VACV strains used during the campaign may be related to outbreaks of bovine vaccinia (BV) (2). In Brazil, BV affects the milk industry and public health services (1,2,4,5). During outbreaks, dairy cattle developed lesions on the teats and udders, causing a decrease in milk production (1,2,4,5).
Another VACV subspecies, buffalopox virus (BPXV), has been isolated from buffaloes (Bubalus bubalis) in rural areas in India and causes clinical signs that resemble those seen during BV outbreaks in Brazil (6). Recent genetic analysis of BPXV samples confirmed its close relationship to VACV-like viruses, although each virus has distinct genetic signatures (1,2,6). Until recently, buffalo herds have been almost exclusive to northern Brazil. However, the buffalo market has experienced great expansion in this country, and today, there are herds in all geographic regions of Brazil. These buffalo herds are hypothetically at risk for VACV infection, on the basis of the outbreaks caused by BPXV that have been described in India (6). To assess the risk for OPV infection in milk buffaloes in Brazil, we conducted a serosurvey of herds from southeastern Brazil, the region most affected by BV.
During October 2010, we screened milk buffalo herds in rural areas of Minas Gerais State, Brazil. Serum samples were collected from 48 female buffaloes used for milk production; these animals belonged to 3 neighboring properties in Carmo da Mata city (20°33′28′′S, 44°52′15′′W), which is in the same mesoregion where the VACV Passatempo virus strain was isolated during an outbreak in 2003 (5). Since then, several outbreaks have been reported in this area.
Serum samples were inactivated, and an OPV plaque-reduction neutralization test (PRNT) was performed (7). The serum titer was defined as the highest dilution that inhibited >70% of viral plaques relative to the level of inhibition of the negative controls. Samples also underwent ELISA for OPV IgG as described (4). Bovine serum samples were used as positive and negative controls (1,4). OPV-PRNT specificity (98.4%) and sensitivity (93.5%) were confirmed by using receiver-operating characteristic analysis as described (8). The tests were performed in duplicate.
Of the 48 buffalo serum samples, 15 (31.25%) contained neutralizing antibodies against OPV; of these, 6 (40%) had titers of 20, 5 (33.3%) had titers of 40, and 4 (26.6%) had titers >80 (Table). The ELISA yielded results similar to those of the PRNT; of the 48 serum samples, 17 (35.41) were IgG positive (Table). A total of 14 samples were coincident in the PRNT and the ELISA, including most of those with high titers by PRNT. To detect viral DNA, we conducted nested PCR to amplify the viral growth factor gene (9) and real-time PCR to amplify the A56R gene (10); results were negative for all 48 serum samples.
We detected antibodies against OPV in buffaloes in Brazil 10 years after the first reported VACV outbreak in cattle in southeastern Brazil (1). Because PRNT and ELISA indicate the presence of OPV antibodies in a nonspecific manner (OPV serologic cross-reaction), it was not possible to determine the species responsible for these results. However, seropositive buffaloes may have been exposed to VACV, the only OPV known to be circulating in Brazil (1,2,4,5,8).
The management of milk buffaloes in Brazil is similar to that of dairy cows, including manual milking (1,4,5). Cow milkers usually work on >2 farms, and the farm infrastructure commonly is unsophisticated (1,4,5). These conditions were shown to be favorable for the spread of VACV among cattle, which suggests that the same conditions could lead to the introduction of VACV into buffalo herds. Because some BV outbreaks are not reported by the farmers, it is not possible to know exactly how or when a buffalo herd in the study area was exposed to the virus. However, milkers who work with both cattle and buffalo may be a route of viral transmission, although other sources of exposure are possible (8). Although no exanthematous VACV outbreaks have been described in milk buffaloes in Brazil, our results suggest that buffalo herds may be exposed to VACV in BV-affected areas and therefore may be at risk for VACV infection. Further research is needed to determine routes of infection, including whether humans working as milkers contribute to virus transmission.
We thank João Rodrigues dos Santos, Ângela Sana Lopes, Ilda Gama, and colleagues from the Laboratório de Vírus for their excellent technical support.
Financial support was provided by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, and Ministério da Agricultura, Pecuária e Abastecimento. F.L.A. received fellowships from CNPq; E.G.K., C.A.B., G.S.T., and P.C.P.F. are researchers supported by CNPq.
- de Souza Trindade G, da Fonseca FG, Marques JT, Nogueira ML, Mendes LC, Borges AS, Araçatuba virus: a vaccinialike virus associated with infection in humans and cattle. Emerg Infect Dis. 2003;9:155–60.
- Damaso CR, Esposito JJ, Condit RC, Moussatche N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology. 2000;277:439–49.
- Damon IK. Poxviruses. In: Knipe DM, Howley PM, editors. Fields virology, 5th ed., vol. II. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2947.
- Silva-Fernandes AT, Travassos CE, Ferreira JM, Abrahão JS, Rocha ES, Viana-Ferreira F, Natural human infections with vaccinia virus during bovine vaccinia outbreaks. J Clin Virol. 2009;44:308–13.
- Leite JA, Drumond BP, Trindade GS, Lobato ZI, da Fonseca FG, dos Santos JR, Passatempo virus, a vaccinia virus strain, Brazil. Emerg Infect Dis. 2005;11:1935–8.
- Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhya R, Gandhale P, Zoonotic infections of buffalopox in India. Zoonoses Public Health. 2010;57:e149–55.
- Newman FK, Frey SE, Blevins TP, Mandava M, Bonifacio A Jr, Yan L, Improved assay to detect neutralizing-antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol. 2003;41:3154–7.
- Abrahão JS, Silva-Fernandes AT, Lima LS, Campos RK, Guedes MI, Cota MM, Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg Infect Dis. 2010;16:976–9.
- Abrahão JS, Lima LS, Assis FL, Alves PA, Silva-Fernandes AT, Cota MM, Nested-multiplex PCR detection of Orthopoxvirus and Parapoxvirus directly from exanthematic clinical samples. Virol J. 2009;6:140.
- de Souza Trindade G, Li Y, Olson VA, Emerson G, Regnery RL, da Fonseca FG, Real-time PCR assay to identify variants of Vaccinia virus: implications for the diagnosis of bovine vaccinia in Brazil. J Virol Methods. 2008;152:63–71.
- Table. Results of testing for orthopoxvirus seropositivity in milk buffalo herds, Minas Gerais State, Brazil, October 2010
Suggested citation for this article: de Assis FL, Pereira G, Oliveira C, Rodrigues GOL, Cotta MMG, Silva-Fernandes AT, et al. Serologic evidence of orthopoxvirus infection in buffaloes, Brazil [letter]. Emerg Infect Dis [serial on the internet]. 2012 Apr [date cited]. http://dx.doi.org/10.3201/eid1804.111800
1These authors contributed equally to this article.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jônatas Abrahão, Laboratório de Vírus, ICB, UFMG, Brazil
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 16, 2012
- Page last updated: March 16, 2012
- Page last reviewed: March 16, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)